The all-in-one platform to find and track your investments
Discover the features
Statistics
Market Cap
141 billion
PE Ratio
14.94 x
Beta (volatility)
0.4
Earnings Per Share
6.85
About
ISIN : FR0000120578
It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Heal
Price
Performance Comparison
| Sanofi SA | |
|---|---|
| 1 year return |
+34 %
|
| 5 years return |
+61 %
|
Valuation
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
Dividend History
Uninter. Dividend
+ 30 yr.
Frequency
1x / year
Dividends in 2022
May
Dividends in 2021
May
May
Dividends in 2021
May
Forward Annual Amount
€3.56
Ex-dividend
5/30/2023
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
Valuation
| Price to Book | Payout ratio | PE Ratio | PEG Ratio |
|---|---|---|---|
| 1.61 | 52 % | 14.94 x | 1.63 |
| Price to Sales | Price / FCF | Enterprise Value Revenue |
|---|---|---|
| 3.11 | 15.31 | 2.90 |
News
Earnings report announcement
4/27/2023
Earnings report announcement
7/28/2023
Earnings report announcement
10/27/2023
FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
9/26/2023
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
9/26/2023
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
9/25/2023
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
9/25/2023
Sanofi Anticipates Significant Hit to Q3 Earnings and Sales Due to Currency Fluctuations
9/22/2023
Sanofi Expects Currency Hit to Sales, Earnings
9/22/2023
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes
9/22/2023
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes
9/22/2023
Sanofi CEO: How AI may ease the pressure of Medicare price negotiations
9/21/2023
AI helping speed up the timeline to create new drugs: Sanofi CEO
9/20/2023
3 Stocks to Buy to Ride Europe’s Coming Market Surge
9/19/2023
UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility
9/19/2023
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2023 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.